ondansetron has been researched along with Lung Neoplasms in 34 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study is to compare the effectiveness of olanzapine combined with ondansetron or ondansetron alone in preventing chemotherapy-induced nausea and vomiting (CINV) of non-small cell lung cancer (NSCLC)." | 9.20 | Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer. ( Wang, H; Wang, L; Wang, X; Zhang, H, 2015) |
| "To assess, in a prospective, observational study, the safety and efficacy of the addition of the neurokinin-1-receptor antagonist (NK1-RA) aprepitant to concomitant radiochemotherapy, for the prophylaxis of radiation therapy-induced nausea and vomiting." | 9.20 | Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin. ( Jahn, F; Jahn, P; Jordan, K; Riesner, A; Sieker, F; Vordermark, D, 2015) |
| "The purpose of this article is to assess the comparative antiemetic efficacy of prochlorperazine, ondansetron, and dexamethasone in the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) after moderately high to highly emetogenic chemotherapy." | 9.11 | Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. ( Amamoo, MA; Bernard, S; Goodin, S; Kane, M; Laliberte, K; Lindley, C; McCune, J; Pham, T; Schell, M; Shord, S; Socinski, MA; Yowell, S, 2005) |
| "We investigated the efficacy of combination of ondansetron hydrochloride injection and tablet against nausea and vomiting in 22 lung cancer patients (total number of chemotherapy courses: 23) receiving chemotherapy of single-dose carboplatin (CBDCA) at a dose of 302." | 9.09 | [Effect of ondansetron hydrochloride injection and tablet against nausea and vomiting in lung cancer patients receiving carboplatin]. ( Miyamoto, Y; Oomasa, M; Teramachi, M; Tomiyama, K; Yagi, K, 1999) |
| "This study was undertaken to further determine the clinical value of ondansetron (OND, supplied by Qilu Pharmaceutical Company) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy." | 9.08 | [Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy]. ( Xu, B; Zhou, A; Zhou, J, 1997) |
| "We examined the efficacy of concurrent use of ondansetron hydrochloride and dexamethasone, and the effective dose of dexamethasone against nausea and vomiting in lung cancer patients receiving chemotherapy including single high dose cisplatin." | 9.08 | [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin]. ( Banba, J; Masaki, M; Tanimura, S; Tomoyasu, H, 1998) |
| "The inhibitory effects of GG032X tablets, a new dosage form (fast dispersing tablet) of ondansetron, 5-HT2 receptor antagonist, on nausea and emesis induced by cisplatin (CDDP), were investigated along with safety and usefulness." | 9.08 | [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis]. ( Akasaka, Y; Ariyoshi, Y; Ikeda, M; Nukariya, N; Ota, J; Suminaga, M; Taguchi, T, 1997) |
| "The anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting was studied in a randomized cross-over trial in 52 patients." | 9.07 | [Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial]. ( Zeng, WY, 1992) |
| "To determine a dose-response relationship of ondansetron for the prevention of emesis induced by high-dose cisplatin and to study the efficacy of the extended dosing schedule of ondansetron during 20 hours after cisplatin administration, 36 patients with malignant neoplasms who had not previously received chemotherapy but who were currently receiving cisplatin were treated." | 9.06 | Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study. ( Bernard, S; Finn, A; Gandara, D; Khojasteh, A; Lester, E; Sartiano, G; Tapazoglou, E, 1990) |
| "Olanzapine is an atypical antipsychotic that has shown efficacy for the treatment of nausea, anxiety, and insomnia." | 7.88 | Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer. ( Lou, G; Wang, W; Zhang, Y, 2018) |
| "The purpose of this study is to examine the risk of uncontrolled chemotherapy-induced nausea/vomiting (CINV) among lung cancer patients receiving multi-day chemotherapy and ondansetron- or palonosetron-initiated prophylactic antiemetic regimens in a community oncology setting." | 7.78 | Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy. ( Balu, S; Buchner, D; Feinberg, B; Gilmore, J; Haislip, S; Jackson, J; Jain, G, 2012) |
| "Palonosetron is a highly potent second-generation selective 5-HT3 receptor antagonist with stronger binding affinity for the 5-HT3 receptor." | 6.76 | Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients. ( Cao, R; Dong, X; Huang, J; Liu, L, 2011) |
| "Ondansetron was superior to metoclopramide for the control of emesis." | 6.68 | [The role of ondansetron (Qilu) in the prevention of non-cisplatin-induced vomiting--a randomized clinical trial]. ( Zeng, W; Zhang, P; Zhou, J, 1995) |
| " From the above, Ondansetron injection which showed sufficient anti-emetic effects on acute emesis and delayed emesis induced by a high single dose or lower multiple doses of cisplatin with its once daily intravenous dose given for 3-5 consecutive days, were considered a safe and clinically useful anti-emetic." | 6.67 | [Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Ondansetron was injected intravenously in a single dose of 4 mg, 8 mg or 12 mg, at 15 minutes before administration of cisplatin." | 6.67 | [Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "and metoclopramide 0." | 5.29 | Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A, 1996) |
| "The objective of this study is to compare the effectiveness of olanzapine combined with ondansetron or ondansetron alone in preventing chemotherapy-induced nausea and vomiting (CINV) of non-small cell lung cancer (NSCLC)." | 5.20 | Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer. ( Wang, H; Wang, L; Wang, X; Zhang, H, 2015) |
| "To assess, in a prospective, observational study, the safety and efficacy of the addition of the neurokinin-1-receptor antagonist (NK1-RA) aprepitant to concomitant radiochemotherapy, for the prophylaxis of radiation therapy-induced nausea and vomiting." | 5.20 | Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin. ( Jahn, F; Jahn, P; Jordan, K; Riesner, A; Sieker, F; Vordermark, D, 2015) |
| "The purpose of this article is to assess the comparative antiemetic efficacy of prochlorperazine, ondansetron, and dexamethasone in the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) after moderately high to highly emetogenic chemotherapy." | 5.11 | Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. ( Amamoo, MA; Bernard, S; Goodin, S; Kane, M; Laliberte, K; Lindley, C; McCune, J; Pham, T; Schell, M; Shord, S; Socinski, MA; Yowell, S, 2005) |
| "We investigated the efficacy of combination of ondansetron hydrochloride injection and tablet against nausea and vomiting in 22 lung cancer patients (total number of chemotherapy courses: 23) receiving chemotherapy of single-dose carboplatin (CBDCA) at a dose of 302." | 5.09 | [Effect of ondansetron hydrochloride injection and tablet against nausea and vomiting in lung cancer patients receiving carboplatin]. ( Miyamoto, Y; Oomasa, M; Teramachi, M; Tomiyama, K; Yagi, K, 1999) |
| "We examined the efficacy of concurrent use of ondansetron hydrochloride and dexamethasone, and the effective dose of dexamethasone against nausea and vomiting in lung cancer patients receiving chemotherapy including single high dose cisplatin." | 5.08 | [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin]. ( Banba, J; Masaki, M; Tanimura, S; Tomoyasu, H, 1998) |
| "This study was undertaken to further determine the clinical value of ondansetron (OND, supplied by Qilu Pharmaceutical Company) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy." | 5.08 | [Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy]. ( Xu, B; Zhou, A; Zhou, J, 1997) |
| "The inhibitory effects of GG032X tablets, a new dosage form (fast dispersing tablet) of ondansetron, 5-HT2 receptor antagonist, on nausea and emesis induced by cisplatin (CDDP), were investigated along with safety and usefulness." | 5.08 | [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis]. ( Akasaka, Y; Ariyoshi, Y; Ikeda, M; Nukariya, N; Ota, J; Suminaga, M; Taguchi, T, 1997) |
| "The anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting was studied in a randomized cross-over trial in 52 patients." | 5.07 | [Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial]. ( Zeng, WY, 1992) |
| "In order to make an objective evaluation of anti-emetic effect, safety and usefulness of ondansetron injection in nausea and vomiting associated with cancer chemotherapy, we carried out a double-blind placebo controlled comparative study in patients receiving high-single dose (50 mg/m2 or more) of cisplatin." | 5.07 | [Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Ondansetron, a selective 5-HT3 receptor antagonist, has already been reported to have a marked effect to alleviate or prevent nausea and vomiting associated with cancer chemotherapy, after its intravenous administration." | 5.07 | [Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "To determine a dose-response relationship of ondansetron for the prevention of emesis induced by high-dose cisplatin and to study the efficacy of the extended dosing schedule of ondansetron during 20 hours after cisplatin administration, 36 patients with malignant neoplasms who had not previously received chemotherapy but who were currently receiving cisplatin were treated." | 5.06 | Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study. ( Bernard, S; Finn, A; Gandara, D; Khojasteh, A; Lester, E; Sartiano, G; Tapazoglou, E, 1990) |
| "Olanzapine is an atypical antipsychotic that has shown efficacy for the treatment of nausea, anxiety, and insomnia." | 3.88 | Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer. ( Lou, G; Wang, W; Zhang, Y, 2018) |
| "The purpose of this study is to examine the risk of uncontrolled chemotherapy-induced nausea/vomiting (CINV) among lung cancer patients receiving multi-day chemotherapy and ondansetron- or palonosetron-initiated prophylactic antiemetic regimens in a community oncology setting." | 3.78 | Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy. ( Balu, S; Buchner, D; Feinberg, B; Gilmore, J; Haislip, S; Jackson, J; Jain, G, 2012) |
| "We used 86Rb+ (K+ analogue) to study potassium influx during the interaction of highly specific 5-HT3-receptor antagonists, ondansetron and granisetron, with the effects of the anticancer drug, estramustine phosphate, on P31 mesothelioma cells." | 3.71 | Diverging effects of 5-HT3 receptor antagonists ondansetron and granisetron on estramustine-inhibited cellular potassium transport. ( Behnam-Motlagh, P; Grankvist, K; Henriksson, R; Sandström, PE, 2001) |
| "Palonosetron is a highly potent second-generation selective 5-HT3 receptor antagonist with stronger binding affinity for the 5-HT3 receptor." | 2.76 | Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients. ( Cao, R; Dong, X; Huang, J; Liu, L, 2011) |
| " Two cases of adverse reactions (hiccups and elevation of ALT and BUN) were observed in the DEX group; however, since the symptoms were all mild, we did not consider there was any problem in safety." | 2.70 | [Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in lung cancer patients on cisplatin]. ( Furue, H; Horichi, N; Ikeda, M; Taguchi, T; Tsukakoshi, S, 2001) |
| "Ondansetron was superior to metoclopramide for the control of emesis." | 2.68 | [The role of ondansetron (Qilu) in the prevention of non-cisplatin-induced vomiting--a randomized clinical trial]. ( Zeng, W; Zhang, P; Zhou, J, 1995) |
| "Ondansetron was injected intravenously in a single dose of 4 mg, 8 mg or 12 mg, at 15 minutes before administration of cisplatin." | 2.67 | [Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| " From the above, Ondansetron injection which showed sufficient anti-emetic effects on acute emesis and delayed emesis induced by a high single dose or lower multiple doses of cisplatin with its once daily intravenous dose given for 3-5 consecutive days, were considered a safe and clinically useful anti-emetic." | 2.67 | [Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Progressive encephalopathy and partial loss of vision were the main observed signs." | 2.39 | Subacute encephalopathic toxicity of cisplatin. ( Conrad, CA; Hong, WK; Verschraegen, C, 1995) |
| "Ifosfamide was administered at the daily dose of 1200 mg/m2/24 h." | 1.29 | [Peri-operative chemotherapy during resection of pulmonary metastases of sarcoma]. ( Azorin, JF; Delepine, G; Delepine, N; Destable, MD; Pocard, M; Tremblay, B, 1994) |
| "and metoclopramide 0." | 1.29 | Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A, 1996) |
| "Ondansetron was non-interactive with the cytotoxicity induced by any of the anti-cancer drugs." | 1.29 | Interaction of the antiemetics ondansetron and granisetron with the cytotoxicity induced by irradiation, epirubicin, bleomycin, estramustine, and cisplatin in vitro. ( Behnam Motlagh, P; Grankvist, K; Henriksson, R, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 18 (52.94) | 18.2507 |
| 2000's | 8 (23.53) | 29.6817 |
| 2010's | 7 (20.59) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, W | 1 |
| Lou, G | 1 |
| Zhang, Y | 1 |
| Wang, X | 1 |
| Wang, L | 1 |
| Wang, H | 1 |
| Zhang, H | 1 |
| Jahn, F | 1 |
| Riesner, A | 1 |
| Jahn, P | 1 |
| Sieker, F | 1 |
| Vordermark, D | 1 |
| Jordan, K | 1 |
| Suzuki, S | 1 |
| Karayama, M | 1 |
| Inui, N | 1 |
| Kuroishi, S | 1 |
| Fujisawa, T | 1 |
| Enomoto, N | 1 |
| Nakamura, Y | 1 |
| Yokomura, K | 1 |
| Toyoshima, M | 1 |
| Imokawa, S | 1 |
| Asada, K | 1 |
| Masuda, M | 1 |
| Yamada, T | 1 |
| Watanabe, H | 1 |
| Hayakawa, H | 1 |
| Suda, T | 1 |
| Dong, X | 1 |
| Huang, J | 2 |
| Cao, R | 1 |
| Liu, L | 1 |
| Feinberg, B | 1 |
| Gilmore, J | 1 |
| Haislip, S | 1 |
| Jackson, J | 1 |
| Jain, G | 1 |
| Balu, S | 1 |
| Buchner, D | 1 |
| Gomez, DR | 1 |
| Liao, KP | 1 |
| Giordano, S | 1 |
| Nguyen, H | 1 |
| Smith, BD | 1 |
| Elting, LS | 1 |
| Lindley, C | 1 |
| Goodin, S | 1 |
| McCune, J | 1 |
| Kane, M | 1 |
| Amamoo, MA | 1 |
| Shord, S | 1 |
| Pham, T | 1 |
| Yowell, S | 1 |
| Laliberte, K | 1 |
| Schell, M | 1 |
| Bernard, S | 2 |
| Socinski, MA | 1 |
| Kosmidis, PA | 1 |
| Kalofonos, HP | 1 |
| Christodoulou, C | 1 |
| Syrigos, K | 1 |
| Makatsoris, T | 1 |
| Skarlos, D | 1 |
| Bakogiannis, C | 1 |
| Nicolaides, C | 1 |
| Bafaloukos, D | 1 |
| Bamias, A | 1 |
| Samantas, E | 1 |
| Xiros, N | 1 |
| Boukovinas, I | 1 |
| Fountzilas, G | 1 |
| Dimopoulos, MA | 1 |
| Behnam Motlagh, P | 1 |
| Henriksson, R | 2 |
| Grankvist, K | 2 |
| Zeng, W | 1 |
| Zhou, J | 3 |
| Zhang, P | 1 |
| Pocard, M | 1 |
| Azorin, JF | 1 |
| Delepine, N | 1 |
| Delepine, G | 1 |
| Tremblay, B | 1 |
| Destable, MD | 1 |
| DiStasio, SA | 1 |
| Verschraegen, C | 1 |
| Conrad, CA | 1 |
| Hong, WK | 1 |
| Gebbia, V | 1 |
| Testa, A | 1 |
| Cannata, G | 1 |
| Gebbia, N | 1 |
| Ariyoshi, Y | 5 |
| Nukariya, N | 1 |
| Akasaka, Y | 5 |
| Suminaga, M | 5 |
| Ota, J | 1 |
| Ikeda, M | 7 |
| Taguchi, T | 7 |
| Tanimura, S | 1 |
| Banba, J | 1 |
| Tomoyasu, H | 1 |
| Masaki, M | 1 |
| Miyamoto, Y | 1 |
| Yagi, K | 1 |
| Teramachi, M | 1 |
| Oomasa, M | 1 |
| Tomiyama, K | 1 |
| Xu, B | 2 |
| Zhou, A | 2 |
| Wang, Z | 1 |
| Zhou, L | 1 |
| Tsavaris, N | 1 |
| Kosmas, CH | 1 |
| Vadiaka, M | 1 |
| Kontos, A | 1 |
| Katsorida, M | 1 |
| Dimitrakopoulos, A | 1 |
| Zerai, A | 1 |
| Koufos, CH | 1 |
| Behnam-Motlagh, P | 1 |
| Sandström, PE | 1 |
| Horichi, N | 1 |
| Furue, H | 6 |
| Tsukakoshi, S | 1 |
| Tsukada, H | 1 |
| Hirose, T | 1 |
| Yokoyama, A | 1 |
| Kurita, Y | 1 |
| Tsukagoshi, S | 5 |
| Fujii, T | 1 |
| Rikimaru, T | 1 |
| Ota, K | 4 |
| Niitani, H | 4 |
| Ohta, J | 4 |
| Zeng, WY | 1 |
| Khojasteh, A | 1 |
| Sartiano, G | 1 |
| Tapazoglou, E | 1 |
| Lester, E | 1 |
| Gandara, D | 1 |
| Finn, A | 1 |
| Grunberg, SM | 1 |
| Stevenson, LL | 1 |
| Russell, CA | 1 |
| McDermed, JE | 1 |
1 review available for ondansetron and Lung Neoplasms
| Article | Year |
|---|---|
Subacute encephalopathic toxicity of cisplatin.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Blindness; Brain Diseases; Ci | 1995 |
23 trials available for ondansetron and Lung Neoplasms
| Article | Year |
|---|---|
Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Carcinoma, Non-Small-Cell Lung; Dr | 2015 |
Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Chemoradiotherapy; Cisplatin; Dexamethasone; Drug Th | 2015 |
Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Bevacizumab; Carbopl | 2016 |
Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Iso | 2011 |
Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast | 2005 |
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2008 |
[The role of ondansetron (Qilu) in the prevention of non-cisplatin-induced vomiting--a randomized clinical trial].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1995 |
[Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administratio | 1997 |
[Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
Topics: Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Administration Schedule; Fe | 1998 |
[Effect of ondansetron hydrochloride injection and tablet against nausea and vomiting in lung cancer patients receiving carboplatin].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Carboplatin; Female; Humans; Inj | 1999 |
[Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1997 |
[Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by cisplatin].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Child; Child, Prescho | 1997 |
[A randomized trial of Zudan in the prophylaxis of nausea and vomiting induced by cisplatin].
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Female; Humans; | 1998 |
Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study.
Topics: Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2001 |
[Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in lung cancer patients on cisplatin].
Topics: Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Femal | 2001 |
Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Combined Modality | 2001 |
[Clinical usefulness of ondansetron injection in patients receiving cancer chemotherapy].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cis | 2002 |
[Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin].
Topics: Adult; Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Female; Gastrointestinal Neoplasm | 1992 |
[Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis].
Topics: Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Drug Evaluation; Female; Gastrointestina | 1992 |
[Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial].
Topics: Adult; Aged; Antiemetics; Breast Neoplasms; Cisplatin; Female; Humans; Lung Neoplasms; Male; Melanom | 1992 |
[Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo].
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Female; Gastrointestinal Neoplasms; Humans; Injections, | 1992 |
[Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo].
Topics: Administration, Oral; Adult; Aged; Cisplatin; Double-Blind Method; Female; Head and Neck Neoplasms; | 1992 |
Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Dose-Response Relationship, Drug; Drug Admin | 1990 |
10 other studies available for ondansetron and Lung Neoplasms
| Article | Year |
|---|---|
Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Anxiety; Benzodiazepines; Cisplatin; Depression; De | 2018 |
Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Prot | 2012 |
Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: a population-based study.
Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Guideline Adhere | 2013 |
Preventing emesis in lung cancer patients.
Topics: Antiemetics; Antineoplastic Agents; Humans; Isoquinolines; Lung Neoplasms; Ondansetron; Palonosetron | 2007 |
Interaction of the antiemetics ondansetron and granisetron with the cytotoxicity induced by irradiation, epirubicin, bleomycin, estramustine, and cisplatin in vitro.
Topics: Animals; Antibiotics, Antineoplastic; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic A | 1995 |
[Peri-operative chemotherapy during resection of pulmonary metastases of sarcoma].
Topics: Adult; Combined Modality Therapy; Female; Humans; Ifosfamide; Infusions, Intravenous; Intraoperative | 1994 |
Zofran makes chemo bearable.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Lung Neoplasms; Nausea; Ondansetron | 1993 |
Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Epirubicin; Female; Hu | 1996 |
Diverging effects of 5-HT3 receptor antagonists ondansetron and granisetron on estramustine-inhibited cellular potassium transport.
Topics: Antiemetics; Antineoplastic Agents; Biological Transport; Bumetanide; Chlorides; Drug Interactions; | 2001 |
Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, | 1989 |